Kymera is running two parallel Phase 2b trials in diseases where dupilumab already owns the conversation, and that tension is exactly what makes the next eighteen months consequential. KT-621, an oral once-daily STAT6 degrader, is now enrolled in BROADEN2 — approximately 200 patients aged 12 to 75 with moderate-to-severe atopic dermatitis, 16-week duration, primary endpoint EASI percent change from baseline — and in BREADTH, 264 adults with moderate-to-severe eosinophilic asthma, 12 weeks, primary endpoint pre-bronchodilator FEV1. Data from those trials are not expected until mid-2027 and late 2027, respectively. That is a long runway to hold.
The Phase 1b AD readout presented at AAD in March is doing real work here. Deep STAT6 degradation confirmed in both blood and skin, measurable reductions in Type 2 inflammatory biomarkers, and clinical signal on EASI alongside patient-reported outcomes in comorbid asthma and allergic rhinitis — all from a single oral agent. The chronic toxicology package in rat and non-human primate, completed this quarter with no adverse findings across all doses, removes one of the more credible failure modes for a first-in-class degrader before Phase 2b enrollment closes. The FDA has now granted Fast Track designation for both AD and asthma, which does not accelerate the science but does formalize the agency’s interest in seeing clean data.
KT-579, the IRF5 degrader aimed at lupus, Sjögren’s, IBD, and RA, is in Phase 1 healthy volunteers with data expected in the second half of 2026. IRF5 is a transcription factor with genuine genetic validation in autoimmunity, and Kymera’s preclinical comparisons against marketed biologics are aggressive claims that Phase 1 PK and safety data alone won’t settle. The program needs to show degradation depth in relevant immune compartments before the disease indication choices become anything more than aspirational.
With $1.55 billion in cash and runway into 2029, execution risk is not financial. The single marker worth tracking is whether BROADEN2 enrollment completes within 2026 as projected — any slip there pushes the mid-2027 readout and directly compresses the gap between KT-621’s data and whatever next-generation IL-4/IL-13 agents are by then in late-stage trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
